George M. Solomon

Flexible, high-resolution micro-optical coherence tomography endobronchial probe toward in vivo imaging of cilia.

An international randomized multicenter comparison of nasal potential difference techniques.

IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.

Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.

Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.

Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.

Pilot evaluation of ivacaftor for chronic bronchitis.

Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.

In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.

Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

A multiple reader scoring system for Nasal Potential Difference parameters.

Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites.

The therapeutic potential of CFTR modulators for COPD and other airway diseases.

MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Seeing cilia: imaging modalities for ciliary motion and clinical connections.

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

CFTR modulator theratyping: Current status, gaps and future directions.